IMNM Historical PE Ratio Notes

— Immunome (ticker: IMNM) is a clinical-stage biotechnology company focused on leveraging the power of the human immune system to develop innovative therapies, particularly in oncology & infectious diseases. By identifying novel antibodies using a proprietary discovery engine, Immunome aims to address unmet medical needs with differentiated therapeutic candidates. When evaluating historical PE (price-to-earnings) ratios for IMNM, it’s important to note that early-stage biotech firms like Immunome often report limited or negative earnings as they invest heavily in research & development rather than generating consistent revenue from marketed products. This means that, historically, Immunome may have exhibited high or even undefined PE ratios during periods of significant clinical investment and before any potential product approvals or partnerships. When reviewing PE ratio trends for IMNM, investors should keep in mind the company's development milestones, clinical trial results, and partnership announcements, which can cause pronounced swings in both share price and earnings figures, leading to volatility in the PE ratio over time. Understanding Immunome's business model & stage of pipeline development is crucial for interpreting historical valuation metrics within the context of the broader biotech sector.

On this page we presented the IMNM Historical PE Ratio information for Immunome' stock. The average IMNM historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average IMNM historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this IMNM historical PE result, against the recent PE: when this page was posted on 6/12/2026, the most recent closing price for IMNM had been 18.38, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on IMNM or any other given stock, valuation analysis for IMNM can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Immunome PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for IMNM. Thanks for visiting, and the next time you need to research IMNM Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.